{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T00:03:20Z","timestamp":1719187400687},"reference-count":59,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2014,6,23]],"date-time":"2014-06-23T00:00:00Z","timestamp":1403481600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2015,1,31]]},"DOI":"10.2217\/fon.14.135","type":"journal-article","created":{"date-parts":[[2014,6,23]],"date-time":"2014-06-23T11:24:20Z","timestamp":1403522660000},"page":"17-26","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":11,"title":["Development of Chronic Myeloid Leukaemia in Patients Treated with Anti-VEGF Therapies for Clear Cell Renal Cell Cancer"],"prefix":"10.1080","volume":"11","author":[{"given":"Anna M","family":"Czarnecka","sequence":"first","affiliation":[{"name":"Department of Oncology with Laboratory of Molecular Oncology, Military Institute of Medicine, Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylwia","family":"Oborska","sequence":"additional","affiliation":[{"name":"Department of Hematology with Stem Cell Transplant Unit, Military Institute of Medicine, Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piotr","family":"Rzepecki","sequence":"additional","affiliation":[{"name":"Department of Hematology with Stem Cell Transplant Unit, Military Institute of Medicine, Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cezary","family":"Szczylik","sequence":"additional","affiliation":[{"name":"Department of Oncology with Laboratory of Molecular Oncology, Military Institute of Medicine, Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2014,6,23]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.01.002"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/SPC.0b013e32832e4681"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2008-0120"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2010.01.003"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-10-1124"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1068"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2844"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-012-9796-8"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2013.2181"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.32.4_suppl.393"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70162-7"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2010.01459.x"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2010-0263"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(03)00182-6"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19961201)78:11<2421::AID-CNCR21>3.0.CO;2-1"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1177\/1078155210382060"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.3747\/co.v16i0.404"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa060655"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa065044"},{"issue":"3","key":"e_1_3_3_22_1","first-page":"1","article-title":"Survival, safety and treatment response duration in \u201creal world\u201d patients with metastatic clear cell renal cancer \u2013 an update from clinical practice","volume":"112","author":"Czarnecka A","year":"2013","unstructured":"Czarnecka A , SobczukP, BoguszK, SpychalskaM, SzczylikC. Survival, safety and treatment response duration in \u201creal world\u201d patients with metastatic clear cell renal cancer \u2013 an update from clinical practice. BJU Int.112(s3), 1\u201317 (2013).","journal-title":"BJU Int."},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1159\/000338175"},{"issue":"3","key":"e_1_3_3_24_1","first-page":"1","article-title":"Development of CML in the course of ccRCC treatment with tyrosine kinase inhibitors \u2013 clinical report with molecular model","volume":"112","author":"Czarnecka AM","year":"2013","unstructured":"Czarnecka AM , OborskaS, RzepeckiP, SzczylikC. Development of CML in the course of ccRCC treatment with tyrosine kinase inhibitors \u2013 clinical report with molecular model. BJU Int.112(s3), 1\u201317 (2013).","journal-title":"BJU Int."},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1159\/000329933"},{"issue":"10","key":"e_1_3_3_26_1","article-title":"Coexistence between renal cell cancer and Hodgkin\u2019s lymphoma: a rare coincidence","volume":"6","author":"Jimenez VH","year":"2006","unstructured":"Jimenez VH . Coexistence between renal cell cancer and Hodgkin\u2019s lymphoma: a rare coincidence. BMC urology6(10), (2006).","journal-title":"BMC urology"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.12.010"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25219"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.1293"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2013.04.001"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.08.021"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-362889"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403874"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.5.1718.1718"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dnarep.2006.05.022"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s004320050228"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2006.10.002"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgq216"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2008.1.436"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-352252"},{"issue":"3","key":"e_1_3_3_41_1","first-page":"85","article-title":"Gene-targeted specific inhibition of chronic myeloid leukemia cell growth by BCR-ABL antisense oligodeoxynucleotides","volume":"29","author":"Skorski T","year":"1991","unstructured":"Skorski T , SzczylikC, MalaguarneraL, CalabrettaB. Gene-targeted specific inhibition of chronic myeloid leukemia cell growth by BCR-ABL antisense oligodeoxynucleotides. Folia Histochem. Cytobiol.29(3), 85\u201389 (1991).","journal-title":"Folia Histochem. Cytobiol."},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1857987"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.97.4.1737"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-423897"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-1066"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02982716"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-11-0004"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.26095"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-228130"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.e11-12-1043"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403779"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201040710"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.4.1101"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1093\/jb\/mvr112"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-379214"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-05-222471"},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.6087"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.1.19"},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404690"},{"issue":"12","key":"e_1_3_3_60_1","first-page":"5225","article-title":"Tyrosine kinase inhibitor-induced macrocytosis","volume":"29","author":"Schallier D","year":"2009","unstructured":"Schallier D , TrullemansF, FontaineC, DecosterL, De GreveJ. Tyrosine kinase inhibitor-induced macrocytosis. Anticancer Res.29(12), 5225\u20135228 (2009).","journal-title":"Anticancer Res."},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23711"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon.14.135","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:43:29Z","timestamp":1719125009000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon.14.135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,23]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1,31]]}},"alternative-id":["10.2217\/fon.14.135"],"URL":"https:\/\/doi.org\/10.2217\/fon.14.135","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,23]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2014-06-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}